Company Overview and News
Tiffany & Co. (TIF - Free Report) is slated to report second-quarter fiscal 2018 results on Aug 28. In the trailing four quarters, this designer, manufacturer and retailer of jewelry and other items has outperformed the Zacks Consensus Estimate by an average of 12%. In the last reported quarter, the company delivered a positive earnings surprise of 35.7%. Investors are counting on another estimate beat by Tiffany in the to-be-reported quarter.
MIK PVH AEO LUXTY
Luxottica Group, S.p.a. ADR (OTCPK:LUXTY) Q2 2018 Earnings Conference Call July 23, 2018 10:00 AM ET
The following slide deck was published by Luxottica Group, S.p.a. ADR in conjunction with their 2018 Q2 earnings call.
2018-06-27 zacks - 1
Industry experts believe that the luxury goods market is likely to remain healthy, courtesy of steady economic growth, higher consumer confidence and rising disposable income. Given this scenario, it will be wise to focus on some luxury goods’ stocks. Here we have highlighted one such stock Tiffany & Co. (TIF - Free Report) , which holds a significant position in the world jewelry market due to its distinctive brand appeal.
MOV GOOS FOSL LUXTY
Tiffany & Co. (TIF) is flexing muscle to counter competition in the jewelry industry. The company, which has a long-term expected earnings growth rate of 11.8%, is banking on several strategic initiatives to enhance customer base.
SCVL URBN FOSL LUXTY
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Tiffany & Co. (TIF - Free Report) is slated to report first-quarter fiscal 2018 results on May 23. In the trailing four quarters, this designer, manufacturer and retailer of jewelry and other items has outperformed the Zacks Consensus Estimate by an average of 4.5%. In the last reported quarter, the company delivered a positive earnings surprise of 2.5%. Investors are counting on another estimate beat by Tiffany in the to-be-reported quarter.
In early 2002, just a few months after he officially took over as the new owner and chief executive officer of Brooks Brothers, Claudio Del Vecchio confronted the reality that the classic American retailer had largely lost its way.
RL NYTAB LUXTY
As competition is intensifying in the retail space, Tiffany & Co. (TIF - Free Report) is leaving no stone unturned to drive revenues. The company, which has a long-term expected earnings growth rate of 11.2%, is banking on several strategic initiatives to enhance customer base. The company's strategic endeavors have helped the stock to gain 8.5% compared with the industry’s decline of 1.2% in the past six months.
JWN ABX KSS M ABX LUXTY
Trade talk and politics could hang over the market in the coming week, even with a blast of earnings news providing a bright spot.
WFCNP DB NTRSP DGX UFPI NTRS MS KSU WFC STT GEC GE STLD UMPQ SYF BHI URI GNE TRI LUXTY
New Look Vision's growth strategy will allow them to take advantage of their economies of scale, as well as secure its position within the increasingly consolidated industry of optical retail.
EYE SAFLF BOSSY FLMNY KATE SAFLY HUGPF FLMNF BCI LUXTY
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET